Brii Biosciences Limited (Stock Code: 2137) Announces Revised Nomination Committee Terms

Bulletin Express11-16

Brii Biosciences Limited (Stock Code: 2137) has released updated Terms of Reference for its Nomination Committee, originally established on June 22, 2021, and now amended effective November 15, 2025.

The Nomination Committee is responsible for identifying and recommending director candidates, overseeing Board performance evaluations, and developing nomination guidelines. Its composition requires a majority of independent non-executive directors, including at least one of a different gender. The Board appoints one member as Chairman, who must also be either the Chairman of the Board or an independent non-executive director.

The revised Terms of Reference outline the Committee’s procedures, including at least one annual meeting and the requirement for minutes to be recorded in sufficient detail. The Committee is authorized to determine processes and criteria for selecting and evaluating candidates, and it may consult external advisors as needed. These updates align with regulatory requirements and are available on the websites of The Stock Exchange of Hong Kong Limited and the Company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184938217?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-16 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184938217","market":"us","top_or_hot":-1,"title":"Brii Biosciences Limited (Stock Code: 2137) Announces Revised Nomination Committee Terms","media":"Bulletin Express","content":"<p>Brii Biosciences Limited (Stock Code: 2137) has released updated Terms of Reference for its Nomination Committee, originally established on June 22, 2021, and now amended effective November 15, 2025.</p>\n<p>The Nomination Committee is responsible for identifying and recommending director candidates, overseeing Board performance evaluations, and developing nomination guidelines. Its composition requires a majority of independent non-executive directors, including at least one of a different gender. The Board appoints one member as Chairman, who must also be either the Chairman of the Board or an independent non-executive director.</p>\n<p>The revised Terms of Reference outline the Committee’s procedures, including at least one annual meeting and the requirement for minutes to be recorded in sufficient detail. The Committee is authorized to determine processes and criteria for selecting and evaluating candidates, and it may consult external advisors as needed. These updates align with regulatory requirements and are available on the websites of The Stock Exchange of Hong Kong Limited and the Company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Limited (Stock Code: 2137) Announces Revised Nomination Committee Terms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Limited (Stock Code: 2137) Announces Revised Nomination Committee Terms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-16 18:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Brii Biosciences Limited (Stock Code: 2137) has released updated Terms of Reference for its Nomination Committee, originally established on June 22, 2021, and now amended effective November 15, 2025.</p>\n<p>The Nomination Committee is responsible for identifying and recommending director candidates, overseeing Board performance evaluations, and developing nomination guidelines. Its composition requires a majority of independent non-executive directors, including at least one of a different gender. The Board appoints one member as Chairman, who must also be either the Chairman of the Board or an independent non-executive director.</p>\n<p>The revised Terms of Reference outline the Committee’s procedures, including at least one annual meeting and the requirement for minutes to be recorded in sufficient detail. The Committee is authorized to determine processes and criteria for selecting and evaluating candidates, and it may consult external advisors as needed. These updates align with regulatory requirements and are available on the websites of The Stock Exchange of Hong Kong Limited and the Company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02137","symbol_name":"腾盛博药-B","start_time":0,"source_url":"","article_id":"1184938217","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184938217","pubTimestamp":1763288511,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Brii Biosciences Limited (Stock Code: 2137) has released updated Terms of Reference for its Nomination Committee, originally established on June 22, 2021, and now amended effective November 15, 2025....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02137":"腾盛博药-B"},"translate_title":"Brii Biosciences Limited（股份代号：2137）公布经修订提名委员会条款","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"Brii Biosciences Limited (Stock Code: 2137) has released updated Terms of Reference for its Nomination Committee, originally established on June 22, 2021, and now amended effective November 15, 2025.\nThe Nomination Committee is responsible for identifying and recommending director candidates, overseeing Board performance evaluations, and developing nomination guidelines. Its composition requires a majority of independent non-executive directors, including at least one of a different gender. The Board appoints one member as Chairman, who must also be either the Chairman of the Board or an independent non-executive director.\nThe revised Terms of Reference outline the Committee’s procedures, including at least one annual meeting and the requirement for minutes to be recorded in sufficient detail. The Committee is authorized to determine processes and criteria for selecting and evaluating candidates, and it may consult external advisors as needed. These updates align with regulatory requirements and are available on the websites of The Stock Exchange of Hong Kong Limited and the Company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184938217","isCrawlerRequest":true}